"Loading Stock Price & Valuation Data ..."
Unlock News Summary by Subscribing to iPick.ai Premium!
Ask anything related to PHAT. [ FAQ on what and how to ask] For non-PHAT questions, click the logo in the upper-right corner to return to the main page and ask there.
CEO:Mr. Steven L. Basta M.B.A.
Headquarter: 100 Campus Drive, Suite 102, Florham Park, NJ, United States, 07932
Industry: Biotechnology, Employees: 427
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
My Watchlist
